

## Summary statistics - quantitative results

(Groups: manufacturer of kit)

Filter: minimal size of groups n = 5

## EQA round: IFT1/18 - Immunophenotypisation

Dead line: 16.04.2018

RoM = robust average	AV = assigned value	Dmax = acceptable percent difference
SD = standard deviation	CRV = certified reference value	LL = lower limit
CV = coefficient of variation	RV = reference value	UL = upper limit
Ntot = total number of participants	CVE = consensus value from experts	Neva = number of evaluated participants
Nout = number of results excluded before calculation	CVP = consensus value from all participants	Nsuc = number of successful participants
	CVPG = consensus value from participants groups	Srel = success (relative)
	U <sub>AV</sub> = expanded uncertainty of the assigned value (k = 2)	

Test	[unit]	Comparability					Comparability							
		RoM	SD	CV [%]	N <sub>tot</sub>	N <sub>out</sub>	AV	U <sub>AV</sub>	D <sub>max</sub>	LL	UL	N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub>
<b>(253) CD 3+ T lymphocytes</b>					100							100	96	96%
Samples and groups	[%]													
<b>Sample A</b>		74,0	1,7	2,3	100	CVP	74	0,41	7%	68,8	79,2	100	99	99%
(12) Beckman Coulter		74,0	1,5	2,1	49	0						49		
(36) Immunotech		72,1	0,320,44		5	0						5		
(88) Becton Dickinson		74,2	1,4	1,9	30	0						30		
(177) MINDRAY		74,0	1,5	2,0	5	0						5		
(190) Exbio Praha		74,4	2,4	3,3	7	0						7		
Other					4	0						4		
							1x 0, 1x 28, 2x 999							
<b>Sample B</b>		74,0	1,5	2,0	100	CVP	74	0,37	7%	68,8	79,2	100	97	97%
(12) Beckman Coulter		73,9	1,3	1,8	49	0						49		
(36) Immunotech		72,3	2,4	3,3	5	0						5		
(88) Becton Dickinson		74,0	1,2	1,6	30	0						30		
(177) MINDRAY		75,0	1,5	2,0	5	0						5		
(190) Exbio Praha		74,4	2,1	2,8	7	0						7		
Other					4	0						4		
							1x 0, 1x 28, 2x 999							
<b>(254) CD 4+ T lymphocytes</b>					100							100	97	97%
Samples and groups	[%]													
<b>Sample A</b>		41,1	1,1	2,8	100	CVP	41,1	0,28	10%	36,9	45,3	100	98	98%
(12) Beckman Coulter		41,1	1,0	2,5	49	0						49		
(36) Immunotech		40,6	1,0	2,6	6	0						6		
(88) Becton Dickinson		41,2	1,1	2,6	29	0						29		
(177) MINDRAY		41,4	0,62	1,5	5	0						5		
(190) Exbio Praha		41,5	1,1	2,7	6	0						6		
Other					5	0						5		
							1x 0, 4x 999							
<b>Sample B</b>		42,4	1,5	3,5	100	CVP	42,4	0,36	10%	38,1	46,7	100	98	98%
(12) Beckman Coulter		42,7	1,2	2,8	49	0						49		
(36) Immunotech		41,4	2,2	5,3	6	0						6		
(88) Becton Dickinson		42,1	1,3	3,1	29	0						29		
(177) MINDRAY		42,7	1,1	2,5	5	0						5		
(190) Exbio Praha		42,6	2,2	5,2	6	0						6		
Other					5	0						5		
							1x 0, 4x 999							
<b>(255) CD 8+ T lymphocytes</b>					100							100	96	96%
Samples and groups	[%]													
<b>Sample A</b>		23,2	1,6	6,9	100	CVP	23,2	0,39	17%	19,2	27,2	100	96	96%
(12) Beckman Coulter		22,7	1,2	5,2	49	0						49		
(36) Immunotech		22,6	2,5	11	6	0						6		
(88) Becton Dickinson		24,1	1,4	6,0	28	0						28		
(177) MINDRAY		23,0	1,5	6,4	5	0						5		
(190) Exbio Praha		23,5	1,8	7,8	6	0						6		
Other					6	0						6		
							1x 0, 1x 28, 4x 999							
<b>Sample B</b>		29,0	1,3	4,6	100	CVP	29	0,33	17%	24	34	100	99	99%
(12) Beckman Coulter		28,7	1,2	4,1	49	0						49		
(36) Immunotech		28,4	1,4	4,9	6	0						6		
(88) Becton Dickinson		29,7	1,5	5,2	28	0						28		
(177) MINDRAY		29,0	1,5	5,1	5	0						5		
(190) Exbio Praha		28,7	1,1	4,0	6	0						6		
Other					6	0						6		
							1x 0, 1x 28, 4x 999							
<b>(256) B lymphocytes</b>					100							100	98	98%
Samples and groups	[%]													
<b>Sample A</b>		17,4	1,3	7,3	100	CVP	17,4	0,31	30%	12,1	22,7	100	98	98%
(12) Beckman Coulter		17,2	1,4	7,9	51	0						51		
(36) Immunotech		16,1	4,2	26	8	0						8		
(88) Becton Dickinson		17,7	0,85	4,8	25	0						25		
(177) MINDRAY		17,5	0,68	3,9	5	0						5		
(190) Exbio Praha		18,4	1,8	9,7	8	0						8		
Other					3	0						3		
							1x 0, 2x 999							
<b>Sample B</b>		9,16	0,75	8,1	100	CVP	9,16	0,18	30%	6,41	12	100	98	98%
(12) Beckman Coulter		9,11	0,72	7,9	51	0						51		
(36) Immunotech		8,22	1,8	21	8	0						8		

## Summary statistics - quantitative results

(Groups: manufacturer of kit)

Filter: minimal size of groups n = 5

## EQA round: IFT1/18 - Immunophenotypisation

Dead line: 16.04.2018

Test	[unit]	RoM	SD	CV [%]	N <sub>tot</sub>	N <sub>out</sub>	Comparability						N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub>
							AV	U <sub>AV</sub>	D <sub>max</sub>	LL	UL				
<b>(256) B lymphocytes</b>					100							100	98	98%	
Samples and groups	[%]														
<b>Sample B</b>		9,16	0,75	8,1	100		CVP	9,16	0,18	30%	6,41	12	100	98	98%
(88) Becton Dickinson		9,16	0,56	6,1	25	0							25		
(177) MINDRAY		10,5	0,74	7,1	5	0							5		
(190) Exbio Praha		9,16	0,83	9,1	8	0							8		
Other					3	0							3		
							1x 0, 2x 999								
<b>(257) NK cells</b>					100							100	92	92%	
Samples and groups	[%]														
<b>Sample A</b>		7,23	1,3	18	100		CVP	7,23	0,33	36%	4,62	9,84	100	94	94%
(12) Beckman Coulter		7,43	1,4	19	49	0							49		
(36) Immunotech		8,07	1,4	18	7	0							7		
(88) Becton Dickinson		7,22	1,0	15	30	0							30		
(177) MINDRAY		7,00	0,00	0,00	5	0							5		
(190) Exbio Praha		5,80	0,30	5,1	6	0							6		
Other					3	0							3		
							1x 0, 2x 999								
<b>Sample B</b>		15,5	1,3	8,6	100		CVP	15,5	0,33	26%	11,4	19,6	100	96	96%
(12) Beckman Coulter		15,7	1,3	8,2	49	0							49		
(36) Immunotech		16,5	5,1	31	7	0							7		
(88) Becton Dickinson		15,4	1,1	7,2	30	0							30		
(177) MINDRAY		15,5	2,2	14	5	0							5		
(190) Exbio Praha		14,7	0,78	5,3	6	0							6		
Other					3	0							3		
							1x 0, 2x 999								

st\_kn\_p

End of report

Printed: 25.04.2018